FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783170811> ?p ?o ?g. }

• W2783170811 endingPage "e1423172" @default.
• W2783170811 startingPage "e1423172" @default.
• W2783170811 abstract "Background: Approximately 50% of melanomas harbor BRAF mutations. Treatment with BRAF +/− MEK inhibition is associated with favorable changes in the tumor microenvironment thus providing the rationale for combining targeted agents with immunotherapy.Methods: Patients with unresectable Stage III or IV BRAFV600E mutant melanoma were enrolled in a single-center prospective study (n = 6). Patients were eligible to receive two courses of HD-IL-2 and vemurafenib twice daily. The primary endpoint was progression-free survival (PFS) with secondary objectives including overall survival (OS), response rates (RR), and safety of combination therapy as compared to historical controls. Immune profiling was performed in longitudinal tissue samples, when available.Results: Overall RR was 83.3% (95% CI: 36%–99%) and 66.6% at 12 weeks. All patients eventually progressed, with three progressing on treatment and three progressing after the vemurafenib continuation phase ended. Median PFS was 35.8 weeks (95% CI: 16–57 weeks). Median OS was not reached; however, the time at which 75% of patients were still alive was 104.4 weeks. Change in circulating BRAFV600E levels correlated with response. Though combination therapy was associated with enhanced CD8 T cell infiltrate, an increase in regulatory T cell frequency was seen with HD-IL-2 administration, suggesting a potential limitation in this strategy.Conclusion: Combination vemurafenib and HD-IL-2 is well tolerated and associated with treatment responses. However, the HD-IL-2 induced increase in Tregs may abrogate potential synergy. Given the efficacy of regimens targeting the PD-1 pathway, strategies combining these regimens with BRAF-targeted therapy are currently underway, and the role of combination vemurafenib and HD-IL-2 is uncertain.Trial Registration: Clinical trial information: NCT01754376; https://clinicaltrials.gov/show/NCT01754376" @default.
• W2783170811 created "2018-01-26" @default.
• W2783170811 creator A5008479799 @default.
• W2783170811 creator A5014864191 @default.
• W2783170811 creator A5015055837 @default.
• W2783170811 creator A5018948216 @default.
• W2783170811 creator A5023174631 @default.
• W2783170811 creator A5030510204 @default.
• W2783170811 creator A5032871350 @default.
• W2783170811 creator A5035427219 @default.
• W2783170811 creator A5036869327 @default.
• W2783170811 creator A5044052948 @default.
• W2783170811 creator A5047185974 @default.
• W2783170811 creator A5049839632 @default.
• W2783170811 creator A5071770314 @default.
• W2783170811 creator A5083431383 @default.
• W2783170811 creator A5088889988 @default.
• W2783170811 date "2018-02-01" @default.
• W2783170811 modified "2023-09-22" @default.
• W2783170811 title "A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma" @default.
• W2783170811 cites W1950572133 @default.
• W2783170811 cites W1965370740 @default.
• W2783170811 cites W1985126564 @default.
• W2783170811 cites W1985312995 @default.
• W2783170811 cites W1997825389 @default.
• W2783170811 cites W2019607817 @default.
• W2783170811 cites W2052781279 @default.
• W2783170811 cites W2060573548 @default.
• W2783170811 cites W2071255079 @default.
• W2783170811 cites W2076668534 @default.
• W2783170811 cites W2080686146 @default.
• W2783170811 cites W2096387850 @default.
• W2783170811 cites W2103027517 @default.
• W2783170811 cites W2103059688 @default.
• W2783170811 cites W2103675014 @default.
• W2783170811 cites W2114903025 @default.
• W2783170811 cites W2116376943 @default.
• W2783170811 cites W2124039716 @default.
• W2783170811 cites W2127269011 @default.
• W2783170811 cites W2128542677 @default.
• W2783170811 cites W2135925159 @default.
• W2783170811 cites W2139276825 @default.
• W2783170811 cites W2139280421 @default.
• W2783170811 cites W2154196978 @default.
• W2783170811 cites W2166262263 @default.
• W2783170811 cites W2169198176 @default.
• W2783170811 cites W2232500106 @default.
• W2783170811 cites W2337664219 @default.
• W2783170811 doi "https://doi.org/10.1080/2162402x.2017.1423172" @default.
• W2783170811 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5927481" @default.
• W2783170811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29721378" @default.
• W2783170811 hasPublicationYear "2018" @default.
• W2783170811 type Work @default.
• W2783170811 sameAs 2783170811 @default.
• W2783170811 citedByCount "23" @default.
• W2783170811 countsByYear W27831708112018 @default.
• W2783170811 countsByYear W27831708112019 @default.
• W2783170811 countsByYear W27831708112020 @default.
• W2783170811 countsByYear W27831708112021 @default.
• W2783170811 countsByYear W27831708112022 @default.
• W2783170811 countsByYear W27831708112023 @default.
• W2783170811 crossrefType "journal-article" @default.
• W2783170811 hasAuthorship W2783170811A5008479799 @default.
• W2783170811 hasAuthorship W2783170811A5014864191 @default.
• W2783170811 hasAuthorship W2783170811A5015055837 @default.
• W2783170811 hasAuthorship W2783170811A5018948216 @default.
• W2783170811 hasAuthorship W2783170811A5023174631 @default.
• W2783170811 hasAuthorship W2783170811A5030510204 @default.
• W2783170811 hasAuthorship W2783170811A5032871350 @default.
• W2783170811 hasAuthorship W2783170811A5035427219 @default.
• W2783170811 hasAuthorship W2783170811A5036869327 @default.
• W2783170811 hasAuthorship W2783170811A5044052948 @default.
• W2783170811 hasAuthorship W2783170811A5047185974 @default.
• W2783170811 hasAuthorship W2783170811A5049839632 @default.
• W2783170811 hasAuthorship W2783170811A5071770314 @default.
• W2783170811 hasAuthorship W2783170811A5083431383 @default.
• W2783170811 hasAuthorship W2783170811A5088889988 @default.
• W2783170811 hasBestOaLocation W27831708111 @default.
• W2783170811 hasConcept C121608353 @default.
• W2783170811 hasConcept C126322002 @default.
• W2783170811 hasConcept C143998085 @default.
• W2783170811 hasConcept C167672396 @default.
• W2783170811 hasConcept C184235292 @default.
• W2783170811 hasConcept C203014093 @default.
• W2783170811 hasConcept C203092338 @default.
• W2783170811 hasConcept C2776131300 @default.
• W2783170811 hasConcept C2777658100 @default.
• W2783170811 hasConcept C2777701055 @default.
• W2783170811 hasConcept C2778472372 @default.
• W2783170811 hasConcept C2778830669 @default.
• W2783170811 hasConcept C2781230642 @default.
• W2783170811 hasConcept C2781249067 @default.
• W2783170811 hasConcept C2994587330 @default.
• W2783170811 hasConcept C31760486 @default.
• W2783170811 hasConcept C502942594 @default.
• W2783170811 hasConcept C535046627 @default.
• W2783170811 hasConcept C57074206 @default.
• W2783170811 hasConcept C71924100 @default.

• next